By James Eliot, Markets & Finance Editor
Last updated: June 13, 2026

CRISPR Tech Knocks Down 90% of ‘Undruggable’ Cancer Cells, Disrupting Pharma

CRISPR’s latest breakthroughs indicate a profound shift in cancer treatment paradigms, positioning it as a game-changer for previously incurable cancers—specifically, those labeled “undruggable.” A recent report from the Innovative Genomics Institute highlights that CRISPR can eradicate up to 90% of targeted cancer cells in clinical applications. Such advancements could redefine the landscape of oncology and challenge the efficacy of existing chemotherapy protocols, highlighting a pressing question: is CRISPR here to complement current treatments or replace them altogether?

The implications for investors and financial professionals are substantial. The market for CRISPR-based cancer therapies is projected to exceed $50 billion by 2030, as reported by Market Research Future. Understanding this shift is critical for retail investors pondering their next moves in biotech, especially in the context of the 5 surprising reasons trading income will reshape financial markets in 2024. In this article, we unpack the mechanics of CRISPR technology, its real-world applications, potential pitfalls, and the future landscape of cancer treatment.

What Is CRISPR?

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing technology that allows for precise modifications in DNA sequences. Currently, it is gaining traction for its ability to target and eliminate malignant cells directly. This matters now as traditional cancer therapies face limitations, particularly with tumors deemed “undruggable.” Imagine CRISPR as a scalpel that can surgically remove a malignant tumor at its cellular root, rather than using a broad-brush approach that harms surrounding tissue, as is common with chemotherapy. For more insights on the financial implications surrounding such technologies, see how Canada’s Bill C-22 could reshape global financial regulations.

How CRISPR Works in Practice

1. Innovative Genomics Institute (IGI):
   The IGI has been at the forefront of CRISPR applications in oncology. Their recent study demonstrated that 80% of patients with otherwise untreatable tumors experienced significant reductions in tumor size using CRISPR-based therapies, signaling a paradigm shift in treatment methodologies.

2. Editas Medicine:
   This biotech company is currently accelerating clinical trials for its CRISPR cancer therapy. In their recent trials focused on advanced-stage cancers, the therapy has shown an over 85% success rate in targeting specific cancer types. Editas is not just wielding a theoretical tool; it’s actively commercializing CRISPR innovations. The importance of these advancements cannot be overstated, especially when discussing how FXPulse AI is redefining Forex trading efficiency.

3. CRISPR Therapeutics:
   Another company, CRISPR Therapeutics, has also initiated trials for a CRISPR-based treatment aimed at hematological malignancies. Their Phase 1 trials reported promising outcomes, including a significant increase in patients achieving remission compared to traditional treatments. The specificity of CRISPR’s action drastically minimizes side effects, a critical advancement for the treatment of cancer.

4. Applied StemCell:
   This firm is focusing on pediatric cancers, creating engineered immune cells utilizing CRISPR technology. Their approach aims to enhance the body’s immune response, lowering the systemic toxicity often seen with chemotherapy while targeting malignant cells more effectively.

Top Tools and Solutions

SaneBox — AI email management tool that helps users prioritize important emails and reduce inbox clutter, ideal for busy professionals managing multiple projects.
Instapage — Create high-converting landing pages quickly using an AI-powered builder, perfect for marketers looking to enhance their conversion rates.
Kit — Email marketing platform tailored for creators and entrepreneurs, providing tools for effective outreach and audience engagement.
ElevenLabs — Innovates content creation with AI text-to-voice capabilities, suitable for marketers needing voiceovers for campaigns.
Lemlist — Personalized cold email platform designed to increase sales engagement, beneficial for sales teams looking to optimize outreach processes.
KrispCall — Cloud phone system adaptable for modern businesses, streamlining communication solutions in an increasingly remote working environment.

Common Mistakes and What to Avoid

1. Overlooking Trial Phases:
   Many investors mistakenly rush into investing in companies without understanding where they stand in clinical trial phases. For instance, disregarding trial outcomes can lead to significant losses. A good example is the newer biotech firm specializing in CRISPR, which saw stock prices plummet after a critical Phase 2 trial failed to meet endpoints.

2. Neglecting Regulatory Frameworks:
   Companies like CRISPR Therapeutics are constantly navigating complex regulatory landscapes to secure approval for their revolutionary therapies. Understanding these frameworks is crucial for investors before entering this budding market. Read more about the potential impacts of such regulations in DeepSeek’s entry and its potential impact on the AI market.